Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tianli
Melbourne, Victoria, Australiatianli-tyre.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
TianLi Biotech is a clinical-stage biotech developing inhaled and orally available small molecule inhibitors targeting CK1δ/ε to treat idiopathic pulmonary fibrosis and other inflammatory/fibrotic lung diseases. The lead program has reached Phase 1 clinical trials, with additional candidates in preclinical development. Early results focus on safety/tolerability and systemic anti-fibrotic activity[3][7].
- Therapeutic areas
- PulmonologyOther
- Modalities
- Small moleculeSmall molecule drug (specifically, proprietary small molecule inhibitors of Casein Kinase 1 delta/epsilon (CK1 δ/ε))
- Industry
- Biotech
02
Partnerships
University of Melbourne[2][3]Beijing No.1 Biotechnology Group Co., Ltd.[2][3]
Beyond the preview
Go deeper on Tianli.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tianli.